Amgen price target raised to $480 from $450 at Oppenheimer
Oppenheimer analyst Jay Olson raised the firm’s price target on Amgen (AMGN) to $480 from $450 and keeps an Outperform rating on the shares ahead of quarterly results. The firm…
Fiscal Year: January - December
Amgen Inc. (AMGN), listed on the NASDAQ, has a market capitalization of $241.81B. As of Oct 23, 2026, the stock is trading at $447.28 per share@else an unavailable price , offering investors a clear view of its current market value. Amgen Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 27.79, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Amgen Inc. also offers a dividend yield of 2.25%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Amgen Inc. (AMGN) has a DCF fair value that is only shown to premium members. To see it, please Login or Upgrade for access.
The proprietary SS Score for Amgen Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Amgen Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Amgen Inc. is 23.77, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Amgen Inc. (AMGN) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Amgen Inc. (AMGN) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Amgen Inc. (AMGN) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Amgen Inc.. To access the full SS Score, consider upgrading your subscription.
Amgen Inc. is a significant player in the industry sector, with a market capitalization of $241.81B and a competitive P/E ratio of 27.79. Investors should compare these metrics with industry peers to gauge whether Amgen Inc. is outperforming or underperforming within its sector.
Oppenheimer analyst Jay Olson raised the firm’s price target on Amgen (AMGN) to $480 from $450 and keeps an Outperform rating on the shares ahead of quarterly results. The firm…
Barclays raised the firm’s price target on Amgen (AMGN) to $400 from $380 and keeps an Equal Weight rating on the shares as part of a Q3 earnings preview. The…
THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ES...
Full results from the Phase III CROSSING trial showed that AstraZeneca (AZN) and Amgen’s (AMGN) TEZSPIRE demonstrated statistically significant and clinically meaningful improvements in the co-primary...
Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved disease remission in 69% of patients with a type of chronic inflammatory disorder of the es...
Symptom Improvements Versus Placebo at Week 24 Were Sustained Through Week 52 Statistically Significant Total Endoscopic Remission with No Visible Inflammation or Fibrosis Attained Versus Placebo at W...
Guggenheim analyst Vamil Divan lowered the firm’s price target on Amgen (AMGN) to $378 from $388 and keeps a Neutral rating on the shares as the firm updated its model…
BMO Capital lowered the firm’s price target on Amgen (AMGN) to $415 from $450 and keeps a Market Perform rating on the shares as part of a broader research note…
BofA analyst Tazeen Ahmad raised the firm’s price target on Amgen (AMGN) to $328 from $317 and keeps an Underperform rating on the shares after updating estimates ahead of the…
Wells Fargo lowered the firm’s price target on Amgen (AMGN) to $430 from $435 following pipeline valuation updates, while keeping an Equal Weight rating on the shares. The firm expects…
UBS raised the firm’s price target on Amgen (AMGN) to $470 from $430 and keeps a Buy rating on the shares. The firm previewed Q3 earnings for the U.S. pharma…
RBC Capital raised the firm’s price target on Amgen (AMGN) to $430 from $400 and keeps an Outperform rating on the shares as part of a broader research note adjusting…
Cantor Fitzgerald raised the firm’s price target on Amgen (AMGN) to $440 from $400 and keeps a Neutral rating on the shares. The consensus long thesis depends on recent commercial…
Truist raised the firm’s price target on Amgen (AMGN) to $380 from $362 and keeps a Hold rating on the shares as part of a broader research note previewing Q3…
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Amgen (AMGN) to $359 from $362 and keeps an Equal Weight rating on the shares. The firm adjusted its…
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
Scotiabank analyst Louise Chen raised the firm’s price target on Amgen (AMGN) to $500 from $450 and keeps an Outperform rating on the shares. The firm notes Amgen’s execution has…
Scotiabank analyst Louise Chen raised the firm’s price target on Amgen (AMGN) to $500 from $450 and keeps an Outperform rating on the shares.
Citi says Amgen’s (AMGN) dazodalibep delivered “positive” Phase 3 results in systemic Sjogren’s, which reduces clinical risk for “a potentially underappreciated I&I asset.” However, several details th...
Amgen (AMGN) announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjogren’s disease and moderate-to-severe systemic disease activity. The study met...
Amgen said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body's moisture-producing glands met the main goal of reducing disease activity in a late-stage trial.
Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity Results Support the Potential for a New, Highly Differentiated Treatment Option f...
Projected from reported cash flow (SEC filings). The starting point is the latest yearly revenue times the median free cash flow margin of the last five years. Years 1 to 5 grow at the revenue growth rate of the last five years (between -5% and 15%), and years 6 to 10 slow down to the 2.5% perpetual growth rate. These are Studying Stocks' own estimates, not analyst forecasts, and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | Source |
|---|---|---|---|
| 2026 | 12.30B | 7.65% | Projected |
| 2027 | 13.24B | 7.65% | Projected |
| 2028 | 14.26B | 7.65% | Projected |
| 2029 | 15.35B | 7.65% | Projected |
| 2030 | 16.52B | 7.65% | Projected |
| 2031 | 17.61B | 6.62% | Projected |
| 2032 | 18.60B | 5.59% | Projected |
| 2033 | 19.45B | 4.56% | Projected |
| 2034 | 20.13B | 3.53% | Projected |
| 2035 | 20.64B | 2.50% | Projected |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 10.39B | 1.00 | 10.39B |
| 2025A | 8.10B | 1.00 | 8.10B |
| 2026E | 12.30B | 1.08 | Login |
| 2027E | 13.24B | 1.16 | Login |
| 2028E | 14.26B | 1.25 | Login |
| 2029E | 15.35B | 1.34 | Login |
| 2030E | 16.52B | 1.45 | Login |
| 2031E | 17.61B | 1.56 | Login |
| 2032E | 18.60B | 1.68 | Login |
| 2033E | 19.45B | 1.81 | Login |
| 2034E | 20.13B | 1.95 | Login |
| 2035E | 20.64B | 2.09 | Login |
| Terminal | 2.09 | Login |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.